Systemic sclerosis: hypothesis-driven treatment strategies
- 26 May 2006
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 367 (9523) , 1683-1691
- https://doi.org/10.1016/s0140-6736(06)68737-0
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Correlation of the degree of dyspnea with health‐related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: Results from the scleroderma lung studyArthritis & Rheumatism, 2005
- Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonistArthritis & Rheumatism, 2004
- Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patientsArthritis & Rheumatism, 2003
- Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodiesArthritis & Rheumatism, 2003
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 1999
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Scleroderma—clinical aspectsJournal of Internal Medicine, 1993
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosisArthritis & Rheumatism, 1988